A success in development of new drug strongly depends on the early stage of the process, namely on the selection of a good lead compound. A failure of several “structure diversity” oriented  drug discovery campaigns turned attention of medicinal chemist to other approaches, including so called privileged structures. According to the original definition the term describes “a single molecular framework able to provide ligands for diverse receptor” (J. Med. Chem. 1988, 31, 2235) and in a more descriptive form relates to “... certain classes of compounds that are highly represented in the overall bioactive compound population, have demonstrated a wealth of biological activity in addition to sound drug-like properties ...” (Comb. Chem. High Through. Scr. 2004, 7, 473).

The concept of privileged  structures will be presented.

• Legal notice:
  

  Copyright (c) Pielaszek Research, all rights reserved.
  The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
  In every case, proper references including Author(s) name(s) and URL of this webpage: https://science24.com/paper/13867 must be provided.

1. Anitiviral activity of chalcones
2. Synthesis of new class of cytotoxic chalcone derivatives
3. Comparison of traditional and new methods of drug discovery
4. CLICK CHEMISTRY? WE LIKE IT